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Background-—There is paucity of knowledge concerning the speciﬁc age in youth when the associations of metabolic syndrome
(MetS) begin to be operative. Thus, we investigated the relation of age to the associations of childhood MetS with adult MetS, type
2 diabetes mellitus and high carotid intima-media thickness.
Methods and Results-—Five thousand eight-hundred three participants were analyzed in 4 cohort studies (Cardiovascular Risk in
Young Finns, Bogalusa Heart Study, Princeton Lipid Research Study, Insulin Study). International cutoffs and previously used
75th percentile cutoffs were used for children to deﬁne MetS and its components. Mean follow-up period was 22.3 years.
Logistic regression was used to calculate risk ratios and 95% conﬁdence intervals. Childhood MetS and overweight were
associated with over 2.4-fold risk for adult MetS from the age of 5 years onward. Risk for type 2 diabetes mellitus was
increased from the age of 8 (risk ratio, 2.6–4.1; 95% conﬁdence interval, 1.35–6.76 and 1.12–7.24, respectively) onward for the
2 childhood MetS criteria based on international cut-off values and for childhood overweight. Risk for high carotid intima-media
thickness was signiﬁcant at ages 11 to 18 years in relation to childhood MetS or overweight (risk ratio, 2.44–4.22; 95%
conﬁdence interval, 1.55–3.55 and 2.55–5.66, respectively). Continuous childhood MetS score was associated with adult MetS
from the age of 5, with type 2 diabetes mellitus from the age of 14 and with high carotid intima-media thickness from the age
of 11 years onward.
Conclusions-—Adult MetS was predicted by MetS in childhood beginning at age 5. However, adult type 2 diabetes mellitus and
subclinical atherosclerosis were not predicted by childhood data until after age 8. Body mass index measurement alone at the
same age points provided similar ﬁndings. ( J Am Heart Assoc. 2017;6:e005632. DOI: 10.1161/JAHA.117.005632.)
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M etabolic syndrome (MetS) is a constellation ofmetabolically interrelated variables, including obesity,
hypertension, dyslipidemia, hyperglycemia, and, in some
analyses, also including hyperinsulinemia.1 It is well known
that adults with MetS are at increased risk of type 2 diabetes
mellitus (T2DM) and cardiovascular disease (CVD).2 The
potential importance of childhood MetS has been outlined
in a consensus statement from the American Heart Associ-
ation3 that noted the need for additional research in children
and adolescents in order to clarify its relation to the
development of adult cardiovascular risk and disease.3
Deﬁning the age when childhood metabolic risk exposure
begins to be associated with adult cardio-metabolic risk and
atherosclerosis would help focus pediatric caregivers on
preventive strategies, including evaluation and intervention.
Using longitudinal data from a collaborative study, we have
previously shown a relation between pediatric MetS and adult
MetS, T2DM, and high carotid artery intima-media thickness
(cIMT), a subclinical marker of atherosclerosis.4 However, the
study did not consider the speciﬁc age or ages in youth when
the association begins to be operative or whether overweight
alone in childhood predicts adult outcomes differentially
according to age of measurement.
In the present study, we used data from 5803 individuals in
4 large, prospective cohort studies participating in the
International Childhood Cardiovascular Cohort (i3C) Consor-
tium5 that have followed participants from childhood into
adulthood. The objective of the study is to examine the age in
childhood when the relationship of childhood MetS and
overweight (according to childhood MetS criteria) is ﬁrst
associated with adult MetS, T2DM, and cIMT. Because there
is no standard deﬁnition for pediatric MetS, we compared 3
previously published deﬁnitions.4,6
Methods
Detailed study characteristics and methods of the 4 cohorts
are described elsewhere. These previous reports also include
analyses of loss to follow-up to show that the representa-
tiveness of the cohorts was maintained.5,7–12
Data were analyzed in 5803 participants from 4 longitu-
dinal cohort studies (YFS [Cardiovascular Risk in Young Finns
Study], BHS [Bogalusa Heart Study], PLRS [Princeton Lipid
Research Study], and IS [Minnesota Insulin Study]) that
measured risk factors of MetS in childhood and adulthood.
Each study was approved by the appropriate institutional
review boards, and written informed consent or assent was
obtained from all the study participants aged >18 or assent
and consent from their parents for participants aged <18.
Data from more than 1 age (maximum, 1 visit per
participant per age group) were entered into the childhood
analyses from the 5803 participants (eg, in YFS, a participant
examined at age 6, 9, and 12 years had data entered into the
analyses from all 3 ages). For subjects with multiple follow-up
visits in adulthood, data from the most recent visit were used
to maximize the length to follow-up.
Details of the methods used for the measurement of
weight, height, blood pressure (BP), lipid levels, glucose and
insulin levels, cIMT, and other covariates in each cohort study
are provided elsewhere.5,7–12 Height and weight were mea-
sured at all time points. Body mass index (BMI) was calculated
from the formula: weight (kg)/height (m)2. A random zero
sphygmomanometer was used to measure BP. Venous blood
samples were taken after a 12-hour fast from the antecubital
vein. In YFS at baseline, serum cholesterol and triglycerides
were measured using fully enzymatic Boehringer CHOD-PAP
kits with an OLLI 3000 analyzer. Subsequently, Olympus
System reagent analyzer in a clinical chemistry analyzer
(AU400; Olympus, Tokyo, Japan) was used to determine lipid
levels. Serum high-density lipoprotein (HDL) cholesterol was
measured by the dextran sulphate 500 000 method. Low-
density lipoprotein cholesterol was calculated using the
Friedewald formula.13 In BHS, HDL-cholesterol and triglyc-
erides were measured using chemical procedures with a
Technicon Auto Analyzer II (Technicon Instrument Corp,
Tarrytown, NY), according to the laboratory manual of the
Lipid Research Clinics program. Since this time, these
variables were determined by enzymatic procedures14 using
the Abbott VP instrument (Abbott Laboratories, North
Chicago, IL). In PLRS data, all serum lipid measurements
were performed with standard methods in Centers for Disease
Control and Prevention–standardized laboratories.15 Child-
hood glucose levels were measured with an ABA-100 system
by using the hexokinase method. In adulthood, glucose levels
were measured with a Dade Dimension Xpand system by
using the hexokinase/glucose-6-phosphate dehydrogenase
method.15,16 In IS, serum lipids were analyzed in the
University of Minnesota laboratory with a Cobas FARA. HDL-
cholesterol was determined after precipitation of non-HDL
lipoproteins with a magnesium/dextran precipitating reagent.
Clinical Perspective
What Is New?
• The data from this study provide help to inform the timing
for initiating clinical screening of cardiovascular risk factors.
What Are the Clinical Implications?
• Evaluation of metabolic risk factor levels provide meaningful
predictionof adult outcomes around the timeof puberty onset.
• Using body mass index alone provides essentially similar
results compared to the conventional metabolic syndrome
model.
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Triglycerides were determined with a standard glycerol
blanked enzymatic triglyceride method. Blood samples were
analyzed for glucose with a Beckman Glucose Analyzer II
(Beckman Instruments Inc, Fullerton, CA). Insulin samples
were determined with a radioimmunoassay kit (Equate RIA;
Binax Corp, Portland, ME). B-mode ultrasound studies of the
left carotid artery were performed at follow-ups using
standardized protocols in each study. In YFS, to assess
intraindividual reproducibility of ultrasound measurements, 57
subjects were re-examined 3 months after the initial visit. The
average absolute difference and SD between measurements
was 0.050.04 mm. In BHS, 75 participants underwent
repeat ultrasound examinations 10 to 12 days after their
initial visit to determine intraindividual reproducibility. The
average absolute difference and SD between measurements
for all cIMT segments was 0.050.03 mm. In IS, repro-
ducibility of the cIMT showed a mean difference (SD) of
0.020.03 for analysis separated by 1 week.
Deﬁnition of MetS and Its Components in
Childhood
Table 1 lists the components and values for the 3 MetS
deﬁnitions used in this study. BMI was used as the measure of
adiposity because waist circumference was not available at
baseline in all cohorts. Fasting insulin was used when glucose
was not available for the YFS, BHS, or IS cohorts at baseline.
We generated age-, sex-, race-, cohort-, and study-year–
speciﬁc percentiles of BMI, systolic and diastolic BPs, HDL-
cholesterol, triglycerides, insulin, and glucose.
For the modiﬁed National Cholesterol Education Program
(MetSNCEP75) deﬁnition, a participant was categorized as
having MetS if he or she had any 3 of the following 5
components: BMI or waist circumference ≥75th percentile;
systolic or diastolic BP ≥75th percentile; HDL-cholesterol
≤25th percentile; triglycerides ≥75th percentile; or insulin/
glucose ≥75th percentile.
The second childhood MetS deﬁnition used age- and sex-
standardized pediatric cut points available in the literature to
denote each component risk factor (MetSPed).4 A participant
was categorized as having MetS if he or she fulﬁlled
overweight plus any 2 of 4 remaining risk component
criteria. Overweight or obesity were deﬁned according to the
Cole classiﬁcation.17 Prehypertension or hypertension was
deﬁned according to the Fourth Report on High Blood
Pressure in Children and Adolescents from the National High
Blood Pressure Education Program.18 Low HDL-cholesterol
and high triglycerides were deﬁned using cut points
proposed from growth-curve data that were linked to adult
deﬁnitions.19 Hyperglycemia was deﬁned as plasma glucose
≥5.60 mmol/L (100 mg/dL).20 Hyperinsulinemia was
deﬁned when glucose was unavailable as having insulin
levels above age-, sex-, race-, study-cohort–, and study-year–
speciﬁc 75th percentile.
The third MetS deﬁnition (MetSCook) was described by
Cook et al21 using the National Cholesterol Education
Program (Adult Treatment Panel III) deﬁnition modiﬁed for
age. Overweight or obesity and elevated BP was deﬁned as
BMI or systolic or diastolic BP ≥90th percentile. Elevated
values for triglycerides were deﬁned at levels at or above
1.695 mmol/L (150 mg/dL) and for glucose levels at or
above 5.6 mmol/L (100 mg/dL); decreased levels of HDL-
cholesterol were deﬁned as levels at or below 1.036 mmol/L
(40 mg/dL). When glucose was not available, we used
hyperinsulinemia (≥90th percentile). Finally, a continuous
MetS score for children was constructed based on a sex- and
race-speciﬁc algorithm derived from conﬁrmatory factor
analysis of data from the National Health and Nutrition
Examination Survey.22 Participants with missing glucose data
were excluded from the continuous MetS analyses.
Table 1. MetS Deﬁnitions and Their Components Used in This Study
MetS Deﬁnition Overweight Elevated BP High Triglyceride Level Low-HDL Cholesterol
Glucose/Insulin
Abnormality
MetSNCEP75 (any 3
components)
BMI ≥75th percentile Systolic and/or diastolic
BP ≥75th percentile
Triglycerides ≥75th
percentile
HDL-cholesterol
≤25th percentile
Glucose or insulin
level ≥75th
percentile
MetSCook (any 3
components)
BMI ≥90th percentile Systolic and/or diastolic
BP ≥90th percentile or
>130/85 mm Hg
≥150 mg/dL ≤40 mg/dL Glucose ≥100 mg/
dL or insulin ≥90th
percentile
MetSPed
(overweight+any 2
components)
Cole classification NHBPEP-classification Growth curve
dependent*
Growth curve
dependent*
Glucose ≥100 mg/
dL or insulin ≥90th
percentile
BP indicates blood pressure; MetS, metabolic syndrome; NCEP, National Cholesterol Education Program; NHBPEP, the National High Blood Pressure Education Program.
*Available only from age of 6 years onward.
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Deﬁnition of MetS in Adulthood
MetS in adulthood was deﬁned by the diagnostic criteria
provided by a joint statement from the International Diabetes
Federation Task Force on Epidemiology and Prevention,
National Heart, Lung and Blood Institute, the American Heart
Association, the World Heart Federation, the International
Atherosclerosis Society, and the International Association for
the Study of Obesity.23 MetS was diagnosed when 3 or more
of the following 5 criteria were present: waist circumference
cut points of ≥102 cm for men and ≥88 cm for women to
deﬁne abdominal obesity; triglycerides ≥1.695 mmol/L
(150 mg/dL); HDL-cholesterol <1.036 mmol/L (40 mg/dL)
in men or <1.295 mmol/L (50 mg/dL) in women; BP ≥130/
≥85 mm Hg or BP-lowering medication; or fasting glucose
≥5.6 mmol/L (100 mg/dL).
Deﬁnition of T2DM in Adulthood
Participants were classiﬁed as having T2DM if they: (1) had a
fasting plasma glucose ≥7.0 mmol/L (≥126 mg/dL); (2) had
a glycohemoglobin (A1C) level of ≥6.5% (48 mmol/mol); (3)
reported receiving oral hypoglycemic agents and/or insulin
injections and did not have type 1 diabetes mellitus; or (4)
reported a history of physician-diagnosed T2DM. Women who
reported having physician-diagnosed diabetes mellitus only
during the term of their pregnancy were considered to have
had gestational diabetes mellitus.
Deﬁnition of High cIMT in Adulthood
Consistent with previous reports,24 high cIMT in adulthood
was deﬁned as a maximum cIMT ≥90th percentile for age-,
sex-, race-, study-year–, and study-cohort–speciﬁc values
(YFS, BHS). For IS, high cIMT in adulthood was deﬁned as a
mean value ≥90th percentile (age, sex, race, and study year)
because maximum values were not available. Data on cIMT
were not available for the PLRS cohort and were excluded
from the analyses examining high cIMT.
Statistical Analysis
The YFS cohort examined children from speciﬁc birth cohorts
with 3-year intervals (ages 3, 6, 9, 12, 15, and 18 years at
baseline survey), whereas the other studies had participants
varying across all ages from 3 to 18 years. Therefore, dictated
by YFS being the largest cohort, individuals from BHS, PLRS,
and IS at age groups of 3 to 4, 5 to 7, 8 to 10, 11 to 13, 14 to 16,
and 17 to 18 years were included in the respective age groups
with the 3-, 6-, 9-, 12-, 15-, and 18-year-olds from YFS. To take
into account possible differences attributed to age, sex, race,
and secular trends in risk factors, study cohort, and different
methodology age-, sex-, race-, study-year–, and study-cohort–
speciﬁc risk factor percentiles were generated for childhood
risk factors. Age- and sex-adjusted ANOVA for continuous
variables and logistic regression for categorical variables was
used to compare characteristics among the study groups. For
main analyses, different multivariate techniques (Poisson
regression with time offset, multinomial regression, Cox
proportional hazards ratios, and logistic regression) were used
to calculate risk ratios (RR) and 95% conﬁdence intervals (95%
CI). Conclusions drawn from the results were essentially similar
independent of the method used. In the Results section, the
values from the logistic regression are shown, which had the
lowest Akaike and Bayesian criterion information values. All
regression analyses using data from both sexes were adjusted
with sex and all regression models combining data from several
cohorts were additionally adjusted for study cohort, and year to
minimize the effect of heterogeneity of the participants
attributed to geography and physiology. Because of almost no
T2DM events were observed in the 2 youngest age groups, we
collapsed these 2 groups (3–4 and 5–7 year olds) into 1 age
group (3–7 year olds) when analyzing future risk of T2DM.
Statistical analyses were performed with SAS software (version
9.4; SAS Institute, Cary, NC). Statistical signiﬁcance was
inferred as P<0.05.
Results
Clinical Characteristics
Table 2 shows the number of childhood visits in each study
cohort and the clinical characteristics of the study subjects.
MeanSD follow-up time was 22.39.5 years. PLRS had the
oldest and IS had the youngest participants at adult follow-up.
Subjects were predominantly whites (76%) and blacks (24%).
Childhood insulin levels, MetSNCEP75, and adulthoodMetS did
not have signiﬁcant differences among the groups (P>0.16).
Otherwise statistically signiﬁcant differences in clinical char-
acteristics were observed among the study groups (P always
<0.05). The normality assumptions of the residuals were
assessed by examining histograms of the residuals and normal
probability plots. The residuals were normally distributed.
Childhood MetS and Overweight Predicting the
Risk for Adult MetS
Tables 3 and 4 show RRs and 95% CIs (sexes combined and
separately, respectively) according to child age (ages 3–18,
divided into 3-year intervals) for childhood MetS prediction of
adult MetS. Childhood MetS was a signiﬁcant predictor of
adult MetS from ages 5 (RR, 2.43–3.39 with 95% CI 1.74–
3.40 and 1.68–6.83, respectively) to 18 years (RR, 3.64–
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5.13; 95% CI, 2.90–4.56 and 3.23–8.15, respectively) for the
3 deﬁnitions, except that the association in males using the
MetSCook deﬁnition did not become signiﬁcant until 8 years
(RR, 4.62; 95% CI, 2.41–8.83). Next, we removed BMI from
the MetSNCEP75 criteria; the results based on any 2 of the
remaining components remained essentially similar to
MetSNCEP75. Finally, a multivariable model including all
individual MetSNCEP75 risk factors was constructed. All
MetSNCEP75 components were signiﬁcant predictors
between ages 5 to 18 years (Table 5). When study cohorts
were analyzed separately, the RRs for childhood MetS in
predicting adulthood MetS were consistent with Table 3
(results shown in Table 6).
Childhood MetS Predicting the Risk for Adult
T2DM
Because of low number of T2DM events, we collapsed 2
youngest age groups (3–4 and 5–7 year olds) into 1 age
group (3–7 year olds). Childhood MetS became a signiﬁcant
Table 2. Characteristics of Study Subjects at Their First Observation in Childhood and Their Most Recent Observation in
Adulthood
BHS IS PLRS YFS
P Value*
All Cohorts
N 1983 322 562 2936 5803
Childhood data
Age, y 11.23.5 14.31.6 12.63.1 10.93.9 <0.0001 11.84.0
Age range, y 3 to 18 11 to 18 6 to 18 3 to 18 3 to 18
Ethinicity (white/black %) 62/38 78/22 71/29 100/0 <0.0001 76/24
BMI, kg/m2 19.34.5 22.85.2 19.94.4 17.93.0 <0.0001 19.24.3
Systolic BP, mm Hg 10211 1089 10413 11111 <0.0001 10612
Diastolic BP, mm Hg 5013 5613 6311 6510 <0.0001 5614
Glucose, mmol/L 4.60.5 4.90.4 4.80.44 4.70.7 <0.0001 4.60.5
Insulin, mU/L 10.48.2 11.58.8  10.06.8 0.16 10.47.6
Triglycerides, mmol/L 0.780.40 1.010.58 0.850.42 0.770.35 <0.0001 0.790.40
HDL-cholesterol, mmol/L 1.500.44 1.130.25 1.390.32 1.600.32 <0.0001 1.510.40
Childhood MetS, %
MetSNCEP75 20 20 20 19 0.16 19
MetSPed 9 14 4 3 <0.0001 6
MetSCook 5 9 14 3 <0.0001 5
Continuous MetS score (mean) 0.950.78 0.100.69 0.710.78 0.670.63 <0.0001 0.830.80
Adulthood data
Age, y 31.38.0 23.32.5 42.16.8 34.48.1 <0.0001 33.28.5
Age range, y 19 to 51 19 to 35 19 to 57 21 to 50 19 to 57
BMI, kg/m2 27.57.1 26.46.5 28.76.9 25.34.7 <0.0001 26.56.2
Systolic BP, mm Hg 11413 11010 12015 11914 <0.0001 11614
Diastolic BP, mm Hg 6911 6510 7911 7311 <0.0001 7111
Glucose, mmol/L 4.70.9 4.80.8 5.01.5 5.20.9 <0.0001 4.91.0
Triglycerides, mmol/L 1.320.95 1.090.63 1.521.47 1.300.94 <0.0001 1.310.97
HDL-cholesterol, mmol/L 1.280.40 1.190.28 1.180.38 1.350.34 <0.0001 1.300.37
MetS, % 20 9 32 25 0.009 23
T2DM, % 1 0 5 2.5 0.17 2
cIMT mean, mm  0.4430.057  0.6030.097 <0.0001 0.5910.104
cIMT maximum, mm 0.7190.192  0.6430.101 <0.0001 0.6720.148
Values are mean (SD), unless otherwise mentioned. BHS indicates the Bogalusa Heart Study; BMI, body mass index; BP, blood pressure; cIMT, carotid intima-media thickness; HDL, high-
density lipoprotein; IS, the Insulin Study; MetS, metabolic syndrome; PLRS, the Princeton Lipid Research Study; YFS, the Cardiovascular Risk in Young Finns Study.
*Age- and sex-adjusted P values from group comparisons.
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predictor of adult T2DM at age 8 years (RR, 2.85–4.14; 95%
CI, 1.12–7.24 and 1.37–12.4, respectively) and continued
through age 18 (RR, 7.63; 95% CI, 3.85–15.1 and 1.98–10.2,
respectively) with the MetSCook, and MetSPed methods.
Detailed results are shown in Table 7. Signiﬁcant associations
between childhood MetS and adulthood T2DM were observed
from 14 years onward by the MetSNCEP75 method (RR, 3.59;
95% CI, 2.09–6.16). When sexes were analyzed separately
(Table 8), the association in females between childhood MetS
and adult T2DM was inconsistent and sporadic, with
MetSCook signiﬁcant at age 11 to 13, MetSPed and
MetSNCEP75 signiﬁcant at age 14 to 16, and MetSPed and
MetSCook signiﬁcant at age 17 to 18. Similar results with
childhood MetS relation to adult T2DM were obtained by
using overweight alone (Table 9). Other MetSNCEP75 risk
factors did not show consistent association with adult T2DM.
When study cohorts were analyzed separately, the outcome
was unreliable, because of almost no outcome events
(Table 10).
Childhood MetS Predicting the Risk for Adult High
cIMT
Childhood MetS measured by all methods predicted adult-
hood high cIMT 2- to 4-fold in the 11 to 18 age groups.
Detailed RR and 95% CI are presented in Table 11. The results
were the same when sexes were analyzed separately
(Table 12). When BMI was removed from the MetSNCEP75
criteria, the association was no longer statistically signiﬁcant
in the 11 to 16 female age groups (P>0.13). From the
MetSNCEP75 risk factors, only high BMI showed consistent
association with adult cIMT from the age of 11 onward
(Table 13). High BP was associated with later intima-media
thickness at ages 5 to 7, high insulin at ages 11 to 16, and
high triglycerides and low HDL cholesterol at ages 14 to 18.
When individual cohorts were analyzed (Table 14), high adult
cIMT was predicted only in YFS and BHS for 11- to 18-year-
olds.
Childhood Continuous MetS Score Predicting the
Risk for Adult MetS, T2DM, and High cIMT
The association between childhood continuous MetS and
adulthood outcomes is shown in Table 15, with the analyses
limited to those with childhood glucose data. The results were
similar to the 3 MetS methods (ie, signiﬁcant for adult MetS at
all ages and signiﬁcant for T2DM and cIMT at adolescent
ages). When sexes were analyzed separately, prediction of the
adult MetS was signiﬁcant from age 5 onward (RR, 2.14; 95%
CI, 1.19–3.85 for males and RR, 3.79; 95% CI, 1.89–7.77 for
females) and high cIMT from age 11 onward (RR, 2.02; 95% CI,
1.20–3.37 for males and RR, 1.82; 95% CI, 1.11–2.98 forTa
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females) for both males and females. Because of the small
number of diabetes mellitus cases, results were inconsistent
in signiﬁcance but consistent in direction. The risk for T2DM
was signiﬁcant for 8 to 10- and 14 to 16-year-old males (RR,
4.19; 95% CI, 1.16–15.1 and RR, 3.40; 95% CI, 1.72–6.71,
respectively) and for 8 to 10- and for 17 to 18-year-old
females (RR, 3.43; 95% CI, 1.32–8.86 and RR, 2.99; 95% CI,
1.34–6.68, respectively).
Discussion
The results from this study demonstrate that childhood MetS
and overweight in both males and females seems to predict
increased risk for adult MetS from age 5 years onward. In
addition, childhood MetS identiﬁes children from ages 8 to
14 years onward who are at increased risk for adult T2DM
and early subclinical atherosclerosis measured by cIMT.
Similar results were found when an MetS score, using MetS
components as continuous variables, was substituted for the
MetS, which uses dichotomized components to deﬁne risk.
We and others have assessed pediatric MetS as a risk
factor for adult MetS, T2DM, and high cIMT in cohorts
consisting of both children and adolescents. A prospective
study of former students from the Princeton lipid research
study reported that children aged 5 to 19 years with MetS
were more likely to have MetS, T2DM, and clinical CVD 25 to
30 years later as adults.10,25 Similar associations were
observed in the YFS and BHS studies concerning MetS,
T2DM, and cIMT.4,6 However, the number of participants in
those studies was too small to be able to consider age-
stratiﬁed analyses, and little is currently known about the age
when childhood MetS exposure begins to relate to adult risk.
The present study, with a cohort of 5803 individuals, shows
that a signiﬁcant relation between childhood MetS and adult
MetS begins as early as age 5 (our data at earlier ages are
sparse and we therefore do not consider them deﬁnitive), and
the relation for T2DM and subclinical atherosclerosis begins in
early adolescence. In contrast to the present study, a 10-year
longitudinal study of 1604 Pima Indians aged 5 to 19 years
with data obtained at age 26 years showed that clustering of
CVD risk factors in 3 childhood age groups (5–9, 10–14, and
15–19 years) increased the risk for early T2DM.26 The slightly
younger age at which a relation to adult T2DM was recognized
may be related to the known increased risk for development
of diabetes mellitus in the Pima population.
A standard universal method for deﬁning pediatric MetS is
not available, and the criteria currently used have been
variably adopted from adult standards.3 In the present report,
we show that the results between 3 different pediatric MetS
deﬁnitions were essentially similar in predicting adult MetS,
T2DM, and cIMT. In addition, the cMetS score, using risk
factors as continuous variables, resulted in ﬁndings similarTa
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(slightly greater discrimination, but harder for clinicians to
use) to the MetS deﬁnitions. In a previous report from YFS,
the prediction of adult T2DM and high cIMT using continuous
MetS scores in youth was no different to a dichotomous MetS
deﬁnition.6 However, among overweight adolescents, it has
been observed that the best model for predicting increased
cIMT was the sum of the quantitative components of MetS
whereas the use of dichotomized MetS variable reduced the
predictive accuracy.27 Concerning the prediction of metabolic
risk factors, the results from the IS study have suggested that
compared to the dichotomous MetS deﬁnition, a continuous
MetS score at the age of 13 years provides more-reliable
prediction of young adult risk of MetS at the age of
22 years.28 The present data suggest that a combined
evaluation of metabolic risk factor levels provides meaningful
prediction of adult outcomes especially after the age of
11 years, that is, around the time of the puberty onset. Based
on the present age-stratiﬁed analyses, we observe that using
BMI alone provides essentially similar results compared with
the conventional MetS model. We have previously shown in
YFS and BHS data that MetS—binary or continuous—does
not seem to contain any additive information beyond the sum
of its components, and it usually does not perform any better
in predicting cardiometabolic risk than BMI alone.4,6 Com-
pared with these previous articles, we now have data from
additional cohorts, with bigger sample size, and more case
numbers. Therefore, we were able to perform age-stratiﬁed
analyses. We found that there is not an age in youth when
MetS outperforms BMI, given that the present data show that
a single assessment of BMI signiﬁcantly predicts adult
outcomes (MetS, T2DM, and high cIMT) at the same age
points compared with MetS. In addition to tracking of
childhood overweight into adulthood,29 possible explanation
for why high BMI alone predicted adult outcomes similar to
MetS in the present study was that BMI is more accurate than
measurements of other components of MetS. It has also been
shown that excess adiposity may precede the development of
other risk factors.4,30 Another explanation may be attributed
to the complex nature of overlapping pathophysiological
mechanisms between the components of MetS.31 Further-
more, childhood MetS has shown to have marked short- and
long-term instability in the categorical diagnosis.3,4,32 Thus,
the clinical utility of MetS deﬁnition may be limited especially
when taking into account the ease and better tractability of
overweight from childhood to adulthood.
An important issue in pediatric preventive care is the age
during childhood when measurement of risk factors can be
related to adult CVD. The data from this study provide help to
inform the timing for initiating clinical screening of cardio-
vascular risk factors. Current pediatric guidelines from the
Expert Panel on Integrated Guidelines for Cardiovascular
Health and Risk Reduction in Children and Adolescents33Ta
bl
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suggest that universal lipid screening in children should be
started between ages 9 to 11 years and testing for fasting
glucose among high-risk individuals at younger ages. The
guidelines further suggest that MetS should not be considered
as a separate entity in childhood or adolescence.33 Our data
are in concert with this recommendation. On the basis of this
study, there seems to be no particular age range in childhood
at which BMI measurements were not associated with
subsequent cardiometabolic outcomes, but MetS would
provide signiﬁcant prediction.
This study had some potential limitations. First, waist
circumference could not be used as a component of the
MetS, because it was not collected at baseline in any of
these cohorts. However, BMI previously has been shown to
give similar results as waist circumference.22,34 Second,
heterogeneity in the methodology and especially cIMT
location and ultrasound protocols existed between the
cohorts. Thus, we attempted to take this heterogeneity into
account by harmonizing our data for clinical characteristics5
and deﬁning risk factors according to age-, sex-, race-,
study-year–, and study-speciﬁc values. cIMT data were
available only among 3 of the cohorts and none of them
had measurements available from childhood. Therefore, we
were not able to analyze longitudinal cIMT data. However,
we have previously shown in the YFS cohort that MetS also
identiﬁes young adults with accelerated cIMT progression
between 2 time points.35 Because the study participants
were comprised of whites and blacks, the results cannot be
directly generalized to other races or ethnic groups.
Because of categorical age structure of the YFS and other
cohorts, age could not be included as a continuous
regression variable in the present study, thus limiting the
ability to assess differences within the ages included in
these groups. Finally, it should be noted that the power to
evaluate associations at the youngest ages was low,
because only the YFS and BHS study speciﬁcally included
children <5 years. The main strength of this study is the
vast database from all 4 studies that included similar
lifestyle and biological risk factors in childhood and
followed the cohorts into adulthood.
In conclusion, this study addresses the utility of MetS in
youth outlined in the scientiﬁc statement from the American
Heart Association3 by providing information on the age at
which childhood MetS begins to identify individuals at
increased risk of developing adult CVD. On the basis of our
results, adult MetS can be predicted beginning at least as
young as age 5, and T2DM and cIMT at or after 8 to 14 years
of age. However, the predictions obtained from the status of
overweight alone were equivalent to childhood MetS deﬁni-
tions. Therefore, in a pediatric setting, BMI measurements
alone seem to provide an easy and informative measure of
subsequent cardiometabolic risk.
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Table 15. Associations Between Childhood Continuous MetS Score and Adulthood Outcomes
Age Group in
Childhood (y)
MetS in Adulthood T2DM in Adulthood High cIMT (≥90th Percentile) in Adulthood
n/N* RR (95% CI) P Value n/N RR (95% CI) P Value n/N RR (95% CI) P Value
5 to 7 53/344 2.69 (1.68–4.31) <0.0001 1/344 0.75 (0.03–12.0) 0.86 5/88 2.07 (0.47–9.07) 0.33
8 to 10 107/491 2.55 (2.00–3.25) <0.0001 7/491 3.64 (1.73–7.62) 0.0006 13/146 1.41 (0.85–2.32) 0.17
11 to 13 179/818 3.12 (2.55–3.81) <0.0001 15/818 1.88 (1.04–3.41) 0.036 27/355 1.90 (1.33–2.71) 0.0004
14 to 16 159/763 3.32 (2.74–4.02) <0.0001 13/763 2.81 (1.67–4.70) <0.0001 39/342 1.99 (1.44–2.74) <0.0001
17 to 18 115/439 3.67 (2.90–4.65) <0.0001 9/439 2.91 (1.58–5.36) 0.0006 21/163 2.39 (1.62–3.53) <0.0001
Data are lacking for 3- to 4-year-olds because of missing glucose data in YFS, BHS, and IS cohorts. All models are adjusted for sex, study cohort, and year. RR values are for 1-SD change in
MetS score. CI indicates conﬁdence interval; cIMT, carotid intima-media thickness; MetS, metabolic syndrome; RR, risk ratio; T2DM, type 2 diabetes mellitus.
*n=Number of events in adulthood, N=Number subjects in each age group with available data in adulthood.
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